{"name":"Janssen Inc.","slug":"janssen-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":800000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Sirturo","genericName":"bedaquiline","slug":"bedaquiline","revenue":400000000,"yoyGrowth":0,"percentOfTotal":50},{"name":"Talvey","genericName":"TALQUETAMAB","slug":"talquetamab","revenue":400000000,"yoyGrowth":0,"percentOfTotal":50}],"timeline":[{"date":"2006-01-01","label":"Prezista first approved","drug":"Prezista","drugSlug":"darunavir","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Intelence first approved","drug":"Intelence","drugSlug":"etravirine","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Sirturo first approved","drug":"Sirturo","drugSlug":"bedaquiline","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Yondelis first approved","drug":"Yondelis","drugSlug":"trabectedin","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Talvey first approved","drug":"Talvey","drugSlug":"talquetamab","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Imaavy first approved","drug":"Imaavy","drugSlug":"nipocalimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-20","label":"Talvey PHASE1 readout","drug":"Talvey","drugSlug":"talquetamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-11-16","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2027-11-16","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2027-11-16","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2027-11-16","label":"Topamax patent expiry (Method of Use)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2027-11-16","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2027-11-16","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2027-11-16","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2027-11-16","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2027-11-16","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2028-03-31","label":"TALVEY Phase 3 readout (Multiple Myeloma)","drug":"TALVEY","drugSlug":"talquetamab-tgvs","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-03-31","label":"TECVAYLI Phase 3 readout (Multiple Myeloma)","drug":"TECVAYLI","drugSlug":"teclistamab-cqyv","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-04-04","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2028-11-02","label":"Sirturo PHASE2 readout","drug":"Sirturo","drugSlug":"bedaquiline","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-12-31","label":"Topamax Phase 3 readout (Non-Convulsive Status Epilepticus)","drug":"Topamax","drugSlug":"topiramate","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-03-30","label":"Talvey PHASE2 readout","drug":"Talvey","drugSlug":"talquetamab","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-03-30","label":"Imaavy PHASE3 readout","drug":"Imaavy","drugSlug":"nipocalimab","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-06-18","label":"RYBREVANT Phase 3 readout (Squamous Cell Carcinoma of Head and Neck)","drug":"RYBREVANT","drugSlug":"amivantamab-vmjw","type":"phase3_readout","sentiment":"neutral"},{"date":"2033-03-19","label":"Topamax patent expiry (Method of Use)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-03-19","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-03-19","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-03-19","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2033-03-19","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2040-08-21","label":"Topamax patent expiry (Method of Use)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2040-08-21","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2040-08-21","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2040-08-21","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"},{"date":"2040-08-21","label":"Topamax patent expiry (Formulation)","drug":"Topamax","drugSlug":"topiramate","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":400000000,"percentOfTotal":50,"drugCount":30,"colorKey":"immunology","drugs":[{"name":"Talvey","genericName":"TALQUETAMAB","slug":"talquetamab","indication":"Relapsed or refractory multiple myeloma","status":"marketed","revenue":400000000},{"name":"Dara SC","genericName":"Dara SC","slug":"dara-sc","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Daratumumab IV","genericName":"Daratumumab IV","slug":"daratumumab-iv","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Daratumumab SC","genericName":"Daratumumab SC","slug":"daratumumab-sc","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Fentanyl-TTS","genericName":"Fentanyl-TTS","slug":"fentanyl-tts","indication":"Chronic pain in opioid-tolerant patients","status":"marketed"},{"name":"VEN","genericName":"VEN","slug":"ven","indication":"Chronic lymphocytic leukemia (CLL), treatment-naïve and relapsed/refractory","status":"marketed"},{"name":"decitabine injection","genericName":"decitabine injection","slug":"decitabine-injection","indication":"Myelodysplastic syndromes (MDS)","status":"marketed"},{"name":"5-Flurouracil","genericName":"5-Flurouracil","slug":"5-flurouracil","indication":"Colorectal cancer","status":"phase_3"},{"name":"Abiraterone Acetate","genericName":"ABIRATERONE","slug":"chembl-chembl254328","indication":"Metastatic castration-resistant prostate cancer (CRPC)","status":"marketed"},{"name":"Abiraterone Acetate (AA)","genericName":"Abiraterone Acetate (AA)","slug":"abiraterone-acetate-aa","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","status":"phase_3"},{"name":"Abiraterone acetate and prednisone","genericName":"Abiraterone acetate and prednisone","slug":"abiraterone-acetate-and-prednisone","indication":"Metastatic castration-resistant prostate cancer","status":"phase_3"},{"name":"Abiraterone: Treatment A","genericName":"Abiraterone: Treatment A","slug":"abiraterone-treatment-a","indication":"Prostate cancer","status":"phase_1"},{"name":"Abiraterone: Treatment C","genericName":"Abiraterone: Treatment C","slug":"abiraterone-treatment-c","indication":"Prostate cancer","status":"phase_1"},{"name":"Amivantamab IV","genericName":"Amivantamab IV","slug":"amivantamab-iv","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Amivantamab Intravenous","genericName":"Amivantamab Intravenous","slug":"amivantamab-intravenous","indication":"Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations","status":"phase_3"},{"name":"Amivantamab SC","genericName":"Amivantamab SC","slug":"amivantamab-sc","indication":"Metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation","status":"phase_2"},{"name":"BCG Vesiculture","genericName":"BCG Vesiculture","slug":"bcg-vesiculture","indication":"Non-muscle invasive bladder cancer (NMIBC), high-grade urothelial carcinoma","status":"phase_3"},{"name":"Cilta-cel OOS Therapy","genericName":"Cilta-cel OOS Therapy","slug":"cilta-cel-oos-therapy","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"Dara IV","genericName":"Dara IV","slug":"dara-iv","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Daratumumab SC: daratumumab + rHuPH20","genericName":"Daratumumab SC: daratumumab + rHuPH20","slug":"daratumumab-sc-daratumumab-rhuph20","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Epo-alpha","genericName":"Epo-alpha","slug":"epo-alpha","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Leucovorin calcium/Levoleucovorin","genericName":"Leucovorin calcium/Levoleucovorin","slug":"leucovorin-calcium-levoleucovorin","indication":"Metastatic colorectal cancer (in combination with fluorouracil)","status":"phase_3"},{"name":"PCI-32765 (Ibrutinib)","genericName":"PCI-32765 (Ibrutinib)","slug":"pci-32765-ibrutinib","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"RYBREVANT","genericName":"AMIVANTAMAB-VMJW","slug":"amivantamab-vmjw","indication":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","status":"marketed"},{"name":"Standard of Care Treatment","genericName":"Standard of Care Treatment","slug":"standard-of-care-treatment","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TALVEY","genericName":"TALQUETAMAB-TGVS","slug":"talquetamab-tgvs","indication":"Relapsed or refractory multiple myeloma","status":"marketed"},{"name":"TAR-200","genericName":"TAR-200","slug":"tar-200","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TAR-210","genericName":"TAR-210","slug":"tar-210","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TECVAYLI","genericName":"TECLISTAMAB-CQYV","slug":"teclistamab-cqyv","indication":"Relapsed or Refractory Multiple Myeloma (Combination Therapy)","status":"marketed"},{"name":"Yondelis","genericName":"TRABECTEDIN","slug":"trabectedin","indication":"Leiomyosarcoma","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":400000000,"percentOfTotal":50,"drugCount":20,"colorKey":"oncology","drugs":[{"name":"Sirturo","genericName":"bedaquiline","slug":"bedaquiline","indication":"Drug resistant tuberculosis","status":"marketed","revenue":400000000},{"name":"Darunavir/Cobicistat (FDC)","genericName":"Darunavir/Cobicistat (FDC)","slug":"darunavir-cobicistat-fdc","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"ODV 25 mg","genericName":"ODV 25 mg","slug":"odv-25-mg","indication":"Chronic Hepatitis C (genotypes 1–6)","status":"discontinued"},{"name":"Ad26.Mos.HIV","genericName":"Ad26.Mos.HIV","slug":"ad26-mos-hiv","indication":"HIV prevention","status":"phase_1"},{"name":"Ad26.RSV.preF-based vaccine","genericName":"Ad26.RSV.preF-based vaccine","slug":"ad26-rsv-pref-based-vaccine","indication":"Prevention of respiratory syncytial virus (RSV) infection in adults","status":"phase_3"},{"name":"DRV/COBI FDC","genericName":"DRV/COBI FDC","slug":"drv-cobi-fdc","indication":"HIV-1 infection in treatment-naive and treatment-experienced patients","status":"phase_3"},{"name":"Darunavir/Ritonavir (DRV/r)","genericName":"Darunavir/Ritonavir (DRV/r)","slug":"darunavir-ritonavir-drv-r","indication":"HIV-1 infection in treatment-experienced patients","status":"phase_3"},{"name":"Efavirenz (EFV)","genericName":"Efavirenz (EFV)","slug":"efavirenz-efv","indication":"HIV-1 infection (in combination with other antiretroviral agents)","status":"marketed"},{"name":"ExPEC9V","genericName":"ExPEC9V","slug":"expec9v","indication":"Prevention of urinary tract infections caused by ExPEC","status":"phase_3"},{"name":"FTC/TDF FDC","genericName":"FTC/TDF FDC","slug":"ftc-tdf-fdc","indication":"HIV-1 infection (treatment)","status":"phase_3"},{"name":"Gynoclin V","genericName":"Gynoclin V","slug":"gynoclin-v","indication":"Bacterial vaginosis","status":"phase_3"},{"name":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","slug":"itcz-oral-solution","indication":"Oropharyngeal candidiasis","status":"phase_3"},{"name":"Odalasvir 25 mg","genericName":"Odalasvir 25 mg","slug":"odalasvir-25-mg","indication":"Chronic hepatitis C virus infection (genotypes 1–6)","status":"discontinued"},{"name":"Odalasvir 75 mg","genericName":"Odalasvir 75 mg","slug":"odalasvir-75-mg","indication":"Chronic hepatitis C (genotype 1)","status":"discontinued"},{"name":"Rilpivirine (RPV)","genericName":"Rilpivirine (RPV)","slug":"rilpivirine-rpv","indication":"Treatment of HIV-1 infection in treatment-naive adults","status":"phase_3"},{"name":"TAF/FTC FDC","genericName":"TAF/FTC FDC","slug":"taf-ftc-fdc","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"TMC114/ritonavir","genericName":"TMC114/ritonavir","slug":"tmc114-ritonavir","indication":"HIV-1 infection in treatment-experienced patients","status":"marketed"},{"name":"TVR","genericName":"TVR","slug":"tvr","indication":"Chronic hepatitis C","status":"phase_3"},{"name":"darunavir (DRV, TMC114)","genericName":"darunavir (DRV, TMC114)","slug":"darunavir-drv-tmc114","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"},{"name":"epoetin alfa + packed RBC transfusion","genericName":"epoetin alfa + packed RBC transfusion","slug":"epoetin-alfa-packed-rbc-transfusion","indication":"Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":117,"colorKey":"cardiovascular","drugs":[{"name":"AAVCAGsCD59","genericName":"AAVCAGsCD59","slug":"aavcagscd59","indication":"Other","status":"phase_1"},{"name":"CNTO 6785","genericName":"CNTO 6785","slug":"cnto-6785","indication":"Other","status":"phase_2"},{"name":"JNJ-55375515 Dose Level 5","genericName":"JNJ-55375515 Dose Level 5","slug":"jnj-55375515-dose-level-5","indication":"Other","status":"phase_1"},{"name":"JNJ-67835989","genericName":"JNJ-67835989","slug":"jnj-67835989","indication":"Other","status":"phase_1"},{"name":"14C-aticaprant","genericName":"14C-aticaprant","slug":"14c-aticaprant","indication":"Other","status":"phase_1"},{"name":"AL-335","genericName":"AL-335","slug":"al-335","indication":"Other","status":"phase_2"},{"name":"ARV Background Regimen","genericName":"ARV Background Regimen","slug":"arv-background-regimen","indication":"Other","status":"phase_2"},{"name":"Active reference comparator","genericName":"Active reference comparator","slug":"active-reference-comparator","indication":"Other","status":"phase_3"},{"name":"Canagliflozin 300 mg","genericName":"Canagliflozin 300 mg","slug":"canagliflozin-300-mg","indication":"Other","status":"marketed"},{"name":"Candin","genericName":"Candin","slug":"candin","indication":"Other","status":"discontinued"},{"name":"Cilta-cel","genericName":"Cilta-cel","slug":"cilta-cel","indication":"Other","status":"marketed"},{"name":"Fentanyl matrix","genericName":"Fentanyl matrix","slug":"fentanyl-matrix","indication":"Other","status":"marketed"},{"name":"GSK2336805 120 mg","genericName":"GSK2336805 120 mg","slug":"gsk2336805-120-mg","indication":"Other","status":"phase_1"},{"name":"INI Based Regimen","genericName":"INI Based Regimen","slug":"ini-based-regimen","indication":"Other","status":"marketed"},{"name":"JNJ-63623872 600 mg","genericName":"JNJ-63623872 600 mg","slug":"jnj-63623872-600-mg","indication":"Other","status":"phase_1"},{"name":"JNJ-63723283","genericName":"JNJ-63723283","slug":"jnj-63723283","indication":"Other","status":"phase_2"},{"name":"ODV 100 mg","genericName":"ODV 100 mg","slug":"odv-100-mg","indication":"Other","status":"phase_1"},{"name":"Rabeprazol","genericName":"Rabeprazol","slug":"rabeprazol","indication":"Duodenal Ulcer due to H. Pylori","status":"discontinued"},{"name":"Treatment C (placebo)","genericName":"Treatment C (placebo)","slug":"treatment-c-placebo","indication":"Used as control comparator in clinical trials across all therapeutic areas","status":"marketed"},{"name":"Xilonix","genericName":"Xilonix","slug":"xilonix","indication":"Other","status":"discontinued"},{"name":"11C-JNJ-63779586","genericName":"11C-JNJ-63779586","slug":"11c-jnj-63779586","indication":"Other","status":"phase_1"},{"name":"14C-JNJ-56136379","genericName":"14C-JNJ-56136379","slug":"14c-jnj-56136379","indication":"Other","status":"phase_1"},{"name":"14C-bleximenib","genericName":"14C-bleximenib","slug":"14c-bleximenib","indication":"Other","status":"phase_1"},{"name":"14C-lazertinib","genericName":"14C-lazertinib","slug":"14c-lazertinib","indication":"Other","status":"phase_1"},{"name":"18F-JNJ-64326067","genericName":"18F-JNJ-64326067","slug":"18f-jnj-64326067","indication":"Other","status":"phase_1"},{"name":"AAV5-hRKp.RPGR","genericName":"AAV5-hRKp.RPGR","slug":"aav5-hrkp-rpgr","indication":"X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations","status":"phase_2"},{"name":"ARX517","genericName":"ARX517","slug":"arx517","indication":"Other","status":"phase_1"},{"name":"Abiraterone: Treatment D","genericName":"Abiraterone: Treatment D","slug":"abiraterone-treatment-d","indication":"Other","status":"phase_1"},{"name":"Ad26.Filo","genericName":"Ad26.Filo","slug":"ad26-filo","indication":"Ebola","status":"phase_1"},{"name":"Ad26.ZEBOV 0.8*10^10 (vp)","genericName":"Ad26.ZEBOV 0.8*10^10 (vp)","slug":"ad26-zebov-0-8-10-10-vp","indication":"Ebola virus disease prevention (Zaire ebolavirus)","status":"phase_3"},{"name":"Ad26.ZEBOV 2*10^10 (vp)","genericName":"Ad26.ZEBOV 2*10^10 (vp)","slug":"ad26-zebov-2-10-10-vp","indication":"Ebola virus disease prevention","status":"phase_3"},{"name":"Ad26.ZIKV.001 1*10^11 vp","genericName":"Ad26.ZIKV.001 1*10^11 vp","slug":"ad26-zikv-001-1-10-11-vp","indication":"Other","status":"phase_1"},{"name":"Ad26.ZIKV.001 5*10^10 vp","genericName":"Ad26.ZIKV.001 5*10^10 vp","slug":"ad26-zikv-001-5-10-10-vp","indication":"Other","status":"phase_1"},{"name":"Aged RPV-LA","genericName":"Aged RPV-LA","slug":"aged-rpv-la","indication":"Other","status":"phase_1"},{"name":"Al(OH)3","genericName":"Al(OH)3","slug":"al-oh-3","indication":"Vaccine adjuvant in phase 3 vaccine development by Janssen Vaccines & Prevention B.V.","status":"phase_3"},{"name":"Ami-HC","genericName":"Ami-HC","slug":"ami-hc","indication":"Other","status":"phase_1"},{"name":"Ami-HC-CF","genericName":"Ami-HC-CF","slug":"ami-hc-cf","indication":"Other","status":"phase_1"},{"name":"Ami-LC","genericName":"Ami-LC","slug":"ami-lc","indication":"Other","status":"phase_1"},{"name":"Antidepressant","genericName":"Antidepressant","slug":"antidepressant","indication":"Other","status":"marketed"},{"name":"Apixaban 2.5 mg","genericName":"Apixaban 2.5 mg","slug":"apixaban-2-5-mg","indication":"Other","status":"marketed"},{"name":"Aticaprant Therapeutic Dose","genericName":"Aticaprant Therapeutic Dose","slug":"aticaprant-therapeutic-dose","indication":"Other","status":"phase_1"},{"name":"Bermekimab Monoclonal Antibody","genericName":"Bermekimab Monoclonal Antibody","slug":"bermekimab-monoclonal-antibody","indication":"Inflammatory conditions (Phase 2 development)","status":"phase_2"},{"name":"Best Supportive Care (BSC)","genericName":"Best Supportive Care (BSC)","slug":"best-supportive-care-bsc","indication":"Other","status":"phase_3"},{"name":"Bridging Therapy","genericName":"Bridging Therapy","slug":"bridging-therapy","indication":"Other","status":"phase_2"},{"name":"Canagliflozin tablets","genericName":"Canagliflozin tablets","slug":"canagliflozin-tablets","indication":"Other","status":"phase_1"},{"name":"Canagliflozin, 100 mg","genericName":"Canagliflozin, 100 mg","slug":"canagliflozin-100-mg","indication":"Other","status":"marketed"},{"name":"Dapoxetine hydrochloride","genericName":"Dapoxetine hydrochloride","slug":"dapoxetine-hydrochloride","indication":"Premature ejaculation in men aged 18-64 years","status":"phase_3"},{"name":"Dexamethasone 20 mg","genericName":"Dexamethasone 20 mg","slug":"dexamethasone-20-mg","indication":"Other","status":"marketed"},{"name":"Erdafitinib Intravesical Delivery System","genericName":"Erdafitinib Intravesical Delivery System","slug":"erdafitinib-intravesical-delivery-system","indication":"Other","status":"phase_1"},{"name":"Esketamine 56 mg","genericName":"Esketamine 56 mg","slug":"esketamine-56-mg","indication":"Other","status":"marketed"},{"name":"Fentanyl D-trans","genericName":"Fentanyl D-trans","slug":"fentanyl-d-trans","indication":"Other","status":"marketed"},{"name":"Fentanyl ITS","genericName":"Fentanyl ITS","slug":"fentanyl-its","indication":"Other","status":"marketed"},{"name":"Genetic: AAV5-hRKp.RPGR","genericName":"Genetic: AAV5-hRKp.RPGR","slug":"genetic-aav5-hrkp-rpgr","indication":"X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations","status":"phase_3"},{"name":"Genetic: AAV5-hRKp.RPGR Intermediate Dose","genericName":"Genetic: AAV5-hRKp.RPGR Intermediate Dose","slug":"genetic-aav5-hrkp-rpgr-intermediate-dose","indication":"X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations","status":"phase_3"},{"name":"Genetic: AAV5-hRKp.RPGR Low Dose","genericName":"Genetic: AAV5-hRKp.RPGR Low Dose","slug":"genetic-aav5-hrkp-rpgr-low-dose","indication":"X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations","status":"phase_3"},{"name":"Guselkumab Intravenous","genericName":"Guselkumab Intravenous","slug":"guselkumab-intravenous","indication":"Other","status":"phase_3"},{"name":"HD quadrivalent influenza vaccine","genericName":"HD quadrivalent influenza vaccine","slug":"hd-quadrivalent-influenza-vaccine","indication":"Prevention of influenza in adults aged 65 years and older","status":"phase_3"},{"name":"ITCZ-IV","genericName":"ITCZ-IV","slug":"itcz-iv","indication":"Invasive aspergillosis","status":"phase_3"},{"name":"Imaavy","genericName":"NIPOCALIMAB","slug":"nipocalimab","indication":"Generalized Myasthenia Gravis (gMG)","status":"marketed"},{"name":"Imvanex","genericName":"Imvanex","slug":"imvanex","indication":"Other","status":"phase_1"},{"name":"JNJ-42756493: Part 1","genericName":"JNJ-42756493: Part 1","slug":"jnj-42756493-part-1","indication":"Other","status":"phase_1"},{"name":"JNJ-54861911","genericName":"JNJ-54861911","slug":"jnj-54861911","indication":"Other","status":"phase_1"},{"name":"JNJ-54861911, 50 mg","genericName":"JNJ-54861911, 50 mg","slug":"jnj-54861911-50-mg","indication":"Other","status":"phase_2"},{"name":"JNJ-54861911-Therapeutic Dose","genericName":"JNJ-54861911-Therapeutic Dose","slug":"jnj-54861911-therapeutic-dose","indication":"Other","status":"phase_1"},{"name":"JNJ-55308942 High Dose","genericName":"JNJ-55308942 High Dose","slug":"jnj-55308942-high-dose","indication":"Other","status":"phase_1"},{"name":"JNJ-56021927 240 Milligram","genericName":"JNJ-56021927 240 Milligram","slug":"jnj-56021927-240-milligram","indication":"Other","status":"phase_1"},{"name":"JNJ-61393215","genericName":"JNJ-61393215","slug":"jnj-61393215","indication":"Other","status":"phase_2"},{"name":"JNJ-64042056","genericName":"JNJ-64042056","slug":"jnj-64042056","indication":"Other","status":"phase_2"},{"name":"JNJ-64565111 Dose Level 1","genericName":"JNJ-64565111 Dose Level 1","slug":"jnj-64565111-dose-level-1","indication":"Other","status":"phase_2"},{"name":"JNJ-64565111 Dose Level 2","genericName":"JNJ-64565111 Dose Level 2","slug":"jnj-64565111-dose-level-2","indication":"Other","status":"phase_2"},{"name":"JNJ-64565111 Dose Level 3","genericName":"JNJ-64565111 Dose Level 3","slug":"jnj-64565111-dose-level-3","indication":"Other","status":"phase_2"},{"name":"JNJ-64991524 Dose Level 8","genericName":"JNJ-64991524 Dose Level 8","slug":"jnj-64991524-dose-level-8","indication":"Other","status":"phase_1"},{"name":"JNJ-67571244","genericName":"JNJ-67571244","slug":"jnj-67571244","indication":"Other","status":"phase_1"},{"name":"JNJ-67953964","genericName":"JNJ-67953964","slug":"jnj-67953964","indication":"Other","status":"phase_2"},{"name":"JNJ-68284528","genericName":"JNJ-68284528","slug":"jnj-68284528","indication":"Other","status":"phase_2"},{"name":"JNJ-78934804","genericName":"JNJ-78934804","slug":"jnj-78934804","indication":"Other","status":"phase_2"},{"name":"JNJ-95475939","genericName":"JNJ-95475939","slug":"jnj-95475939","indication":"Other","status":"phase_2"},{"name":"JNS001","genericName":"JNS001","slug":"jns001","indication":"Other","status":"phase_3"},{"name":"Ketoconazole 200 mg","genericName":"Ketoconazole 200 mg","slug":"ketoconazole-200-mg","indication":"Other","status":"phase_1"},{"name":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","genericName":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","slug":"mva-bn-filo-1-10-8-infectious-unit-inf-u","indication":"Prevention of Ebola virus disease","status":"phase_3"},{"name":"MVA-BN-Filo 5*10^7 Inf. U.","genericName":"MVA-BN-Filo 5*10^7 Inf. U.","slug":"mva-bn-filo-5-10-7-inf-u","indication":"Prevention of Ebola virus disease","status":"phase_3"},{"name":"Matching Placebo to JNJ-77242113","genericName":"Matching Placebo to JNJ-77242113","slug":"matching-placebo-to-jnj-77242113","indication":"Other","status":"phase_3"},{"name":"Matching Placebo to Ustekinumab","genericName":"Matching Placebo to Ustekinumab","slug":"matching-placebo-to-ustekinumab","indication":"Other","status":"phase_3"},{"name":"Matching placebo to Seltorexant","genericName":"Matching placebo to Seltorexant","slug":"matching-placebo-to-seltorexant","indication":"Matching placebo control for Seltorexant clinical trials (not a therapeutic agent)","status":"phase_3"},{"name":"Miconazole plus Hydrocortisone","genericName":"Miconazole plus Hydrocortisone","slug":"miconazole-plus-hydrocortisone","indication":"Other","status":"marketed"},{"name":"Nucynta ER","genericName":"Nucynta ER","slug":"nucynta-er","indication":"Other","status":"marketed"},{"name":"Oxybutynin chloride OROS","genericName":"Oxybutynin chloride OROS","slug":"oxybutynin-chloride-oros","indication":"Other","status":"marketed"},{"name":"PP6M injection Dose 1","genericName":"PP6M injection Dose 1","slug":"pp6m-injection-dose-1","indication":"Contraception in women of reproductive age","status":"phase_3"},{"name":"Placebo (20% Intralipid)","genericName":"Placebo (20% Intralipid)","slug":"placebo-20-intralipid","indication":"Other","status":"phase_3"},{"name":"Placebo A (After CP)","genericName":"Placebo A (After CP)","slug":"placebo-a-after-cp","indication":"Other","status":"phase_3"},{"name":"Placebo B (After CP)","genericName":"Placebo B (After CP)","slug":"placebo-b-after-cp","indication":"Other","status":"phase_3"},{"name":"Placebo and prednisone","genericName":"Placebo and prednisone","slug":"placebo-and-prednisone","indication":"Active comparator arm in phase 3 clinical trial (specific indication unknown)","status":"phase_3"},{"name":"Placebo for Adalimumab","genericName":"Placebo for Adalimumab","slug":"placebo-for-adalimumab","indication":"Control arm in Phase 3 clinical trial for adalimumab (TNF-alpha inhibitor)","status":"phase_3"},{"name":"Placebo for Niraparib","genericName":"Placebo for Niraparib","slug":"placebo-for-niraparib","indication":"Control arm in Phase 3 clinical trial for Niraparib","status":"phase_3"},{"name":"Placebo for Ustekinumab","genericName":"Placebo for Ustekinumab","slug":"placebo-for-ustekinumab","indication":"Control arm in Phase 3 clinical trial of ustekinumab (active comparator)","status":"phase_3"},{"name":"Placebo for guselkumab","genericName":"Placebo for guselkumab","slug":"placebo-for-guselkumab","indication":"Other","status":"phase_3"},{"name":"Propranolol booster","genericName":"Propranolol booster","slug":"propranolol-booster","indication":"Other","status":"marketed"},{"name":"Quadrivalent High-dose Influenza Vaccine","genericName":"Quadrivalent High-dose Influenza Vaccine","slug":"quadrivalent-high-dose-influenza-vaccine","indication":"Prevention of influenza disease in adults 65 years of age and older","status":"phase_3"},{"name":"RSV preF Protein 50 mcg","genericName":"RSV preF Protein 50 mcg","slug":"rsv-pref-protein-50-mcg","indication":"Other","status":"phase_1"},{"name":"Rilpivirine formulation G009-01","genericName":"Rilpivirine formulation G009-01","slug":"rilpivirine-formulation-g009-01","indication":"Other","status":"phase_1"},{"name":"Risperidone prolonged release","genericName":"Risperidone prolonged release","slug":"risperidone-prolonged-release","indication":"Other","status":"marketed"},{"name":"Sulphonylruea","genericName":"Sulphonylruea","slug":"sulphonylruea","indication":"Other","status":"phase_3"},{"name":"Sulphonylurea","genericName":"Sulphonylurea","slug":"sulphonylurea","indication":"Other","status":"marketed"},{"name":"TTS-fentanyl","genericName":"TTS-fentanyl","slug":"tts-fentanyl","indication":"Other","status":"marketed"},{"name":"Tacrolimus With Diet and Exercise Intervention","genericName":"Tacrolimus With Diet and Exercise Intervention","slug":"tacrolimus-with-diet-and-exercise-intervention","indication":"Other","status":"marketed"},{"name":"Topiramate Slow","genericName":"Topiramate Slow","slug":"topiramate-slow","indication":"Other","status":"marketed"},{"name":"Tramadol HCl, 50 mg","genericName":"Tramadol HCl, 50 mg","slug":"tramadol-hcl-50-mg","indication":"Other","status":"phase_1"},{"name":"Tramadol Hydrochloride Plus Acetaminophen","genericName":"Tramadol Hydrochloride Plus Acetaminophen","slug":"tramadol-hydrochloride-plus-acetaminophen","indication":"Other","status":"marketed"},{"name":"Treatment C: abiraterone acetate","genericName":"Treatment C: abiraterone acetate","slug":"treatment-c-abiraterone-acetate","indication":"Other","status":"phase_1"},{"name":"Treatment sequence 2","genericName":"Treatment sequence 2","slug":"treatment-sequence-2","indication":"Other","status":"phase_1"},{"name":"Vagitrol V","genericName":"Vagitrol V","slug":"vagitrol-v","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"[18F]MNI-1020","genericName":"[18F]MNI-1020","slug":"18f-mni-1020","indication":"Other","status":"phase_1"},{"name":"antipsychotics","genericName":"antipsychotics","slug":"antipsychotics","indication":"Other","status":"marketed"},{"name":"early initiation of treatment with Risperdal Consta","genericName":"early initiation of treatment with Risperdal Consta","slug":"early-initiation-of-treatment-with-risperdal-consta","indication":"Other","status":"marketed"},{"name":"haloperidole","genericName":"haloperidole","slug":"haloperidole","indication":"Other","status":"marketed"},{"name":"routine initiation of treatment with Risperdal Consta","genericName":"routine initiation of treatment with Risperdal Consta","slug":"routine-initiation-of-treatment-with-risperdal-consta","indication":"Other","status":"marketed"},{"name":"topiramate; almotriptan malate","genericName":"topiramate; almotriptan malate","slug":"topiramate-almotriptan-malate","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":17,"colorKey":"infectious","drugs":[{"name":"Ultram","genericName":"tramadol","slug":"tramadol","indication":"Chronic pain","status":"marketed"},{"name":"Ustekinumab (90 mg)","genericName":"Ustekinumab (90 mg)","slug":"ustekinumab-90-mg","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Adalimumab (40 mg)","genericName":"Adalimumab (40 mg)","slug":"adalimumab-40-mg","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Anti TNF therapy including infliximab","genericName":"Anti TNF therapy including infliximab","slug":"anti-tnf-therapy-including-infliximab","indication":"Rheumatoid Arthritis","status":"phase_2"},{"name":"CNTO 148","genericName":"CNTO 148","slug":"cnto-148","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CNTO 1959","genericName":"CNTO 1959","slug":"cnto-1959","indication":"Psoriasis","status":"phase_2"},{"name":"Cosentyx","genericName":"Cosentyx","slug":"cosentyx","indication":"Ankylosing spondylitis","status":"marketed"},{"name":"Guselkumab Dose 1","genericName":"Guselkumab Dose 1","slug":"guselkumab-dose-1","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Guselkumab Subcutaneous","genericName":"Guselkumab Subcutaneous","slug":"guselkumab-subcutaneous","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Intelence","genericName":"ETRAVIRINE","slug":"etravirine","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"JNJ-79635322","genericName":"JNJ-79635322","slug":"jnj-79635322","indication":"Psoriasis","status":"phase_3"},{"name":"Nipocalimab SC-LIV","genericName":"Nipocalimab SC-LIV","slug":"nipocalimab-sc-liv","indication":"Generalized myasthenia gravis (gMG)","status":"phase_3"},{"name":"Prezista","genericName":"DARUNAVIR","slug":"darunavir","indication":"Human immunodeficiency virus infection","status":"marketed"},{"name":"Ustekinumab - Half-Standard Dosage","genericName":"Ustekinumab - Half-Standard Dosage","slug":"ustekinumab-half-standard-dosage","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Ustekinumab IV","genericName":"Ustekinumab IV","slug":"ustekinumab-iv","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Ustekinumab SC","genericName":"Ustekinumab SC","slug":"ustekinumab-sc","indication":"Plaque psoriasis","status":"phase_3"},{"name":"aspirin (ASA)","genericName":"aspirin (ASA)","slug":"aspirin-asa","indication":"Acute myocardial infarction","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"rare","drugs":[{"name":"PP1M","genericName":"PP1M","slug":"pp1m","indication":"Schizophrenia","status":"phase_3"},{"name":"Risperidone long acting injectables","genericName":"Risperidone long acting injectables","slug":"risperidone-long-acting-injectables","indication":"Schizophrenia","status":"marketed"},{"name":"double blind PR OROS methylphenidate","genericName":"double blind PR OROS methylphenidate","slug":"double-blind-pr-oros-methylphenidate","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_3"},{"name":"Atomoxetine (ATO)","genericName":"Atomoxetine (ATO)","slug":"atomoxetine-ato","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults","status":"marketed"},{"name":"Concerta AG formulation","genericName":"Concerta AG formulation","slug":"concerta-ag-formulation","indication":"Attention Deficit Hyperactivity Disorder (ADHD)","status":"phase_2"},{"name":"Concerta EG formulation","genericName":"Concerta EG formulation","slug":"concerta-eg-formulation","indication":"Attention Deficit Hyperactivity Disorder (ADHD)","status":"phase_2"},{"name":"Galantamine (Reminyl)","genericName":"Galantamine (Reminyl)","slug":"galantamine-reminyl","indication":"Mild to moderate Alzheimer's disease","status":"marketed"},{"name":"Intravenous Esketamine","genericName":"Intravenous Esketamine","slug":"intravenous-esketamine","indication":"Treatment-resistant depression (TRD)","status":"marketed"},{"name":"JNJ-77242113","genericName":"JNJ-77242113","slug":"jnj-77242113","indication":"Schizophrenia","status":"phase_3"},{"name":"Matching placebo to Quetiapine XR","genericName":"Matching placebo to Quetiapine XR","slug":"matching-placebo-to-quetiapine-xr","indication":"Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial)","status":"phase_3"},{"name":"Oxybutinin Extended-Release","genericName":"Oxybutinin Extended-Release","slug":"oxybutinin-extended-release","indication":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency","status":"marketed"},{"name":"Paliperdidone ER","genericName":"Paliperdidone ER","slug":"paliperdidone-er","indication":"Schizophrenia","status":"marketed"},{"name":"Risperidone Long acting injectable","genericName":"Risperidone Long acting injectable","slug":"risperidone-long-acting-injectable","indication":"Schizophrenia","status":"marketed"},{"name":"Topamax","genericName":"topiramate","slug":"topiramate","indication":"Epilepsy characterized by intractable complex partial seizures","status":"marketed"},{"name":"Topiramate Standard","genericName":"Topiramate Standard","slug":"topiramate-standard","indication":"Epilepsy / seizure disorders","status":"marketed"},{"name":"open label PR OROS methylphenidate","genericName":"open label PR OROS methylphenidate","slug":"open-label-pr-oros-methylphenidate","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"neuroscience","drugs":[{"name":"Hydromorphone HCI OROS","genericName":"Hydromorphone HCI OROS","slug":"hydromorphone-hci-oros","indication":"Moderate to severe pain","status":"phase_2"},{"name":"Hydromorphone HCl OROS","genericName":"Hydromorphone HCl OROS","slug":"hydromorphone-hcl-oros","indication":"Moderate to severe chronic pain requiring around-the-clock opioid therapy","status":"marketed"},{"name":"OROS hydromorphone HCl","genericName":"OROS hydromorphone HCl","slug":"oros-hydromorphone-hcl","indication":"Moderate to severe chronic pain requiring continuous opioid therapy","status":"marketed"},{"name":"Tramadol HCI/acetaminophen","genericName":"Tramadol HCI/acetaminophen","slug":"tramadol-hci-acetaminophen","indication":"Moderate to moderately severe pain","status":"marketed"},{"name":"Tramadol HCl/Acetaminophen IR","genericName":"Tramadol HCl/Acetaminophen IR","slug":"tramadol-hcl-acetaminophen-ir","indication":"Moderate to moderately severe pain","status":"phase_3"},{"name":"Tramadol HCl/acetaminophen Extended Release","genericName":"Tramadol HCl/acetaminophen Extended Release","slug":"tramadol-hcl-acetaminophen-extended-release","indication":"Moderate to moderately severe pain (chronic pain management)","status":"marketed"},{"name":"Tramadol hydrochloride/ Acetaminophen","genericName":"Tramadol hydrochloride/ Acetaminophen","slug":"tramadol-hydrochloride-acetaminophen","indication":"Moderate pain","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"respiratory","drugs":[{"name":"JNS020QD","genericName":"JNS020QD","slug":"jns020qd","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Antihyperglycemic agent(s)","genericName":"Antihyperglycemic agent(s)","slug":"antihyperglycemic-agent-s","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Metformin immediate release","genericName":"Metformin immediate release","slug":"metformin-immediate-release","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Sulfonylureas (SU)","genericName":"Sulfonylureas (SU)","slug":"sulfonylureas-su","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"Sirturo","genericName":"bedaquiline","slug":"bedaquiline","phase":"marketed","mechanism":"Sirturo works by blocking the potassium voltage-gated channel subfamily H member 2, which is essential for the survival of Mycobacterium tuberculosis bacteria.","indications":["Drug resistant tuberculosis","Pulmonary tuberculosis"],"catalyst":""},{"name":"Talvey","genericName":"TALQUETAMAB","slug":"talquetamab","phase":"marketed","mechanism":"Talquetamab binds to the T-cell surface glycoprotein CD3, triggering a response that kills cancer cells.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"AAVCAGsCD59","genericName":"AAVCAGsCD59","slug":"aavcagscd59","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CNTO 6785","genericName":"CNTO 6785","slug":"cnto-6785","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hydromorphone HCI OROS","genericName":"Hydromorphone HCI OROS","slug":"hydromorphone-hci-oros","phase":"phase_2","mechanism":"μ-opioid receptor agonist","indications":["Moderate to severe pain"],"catalyst":""},{"name":"JNJ-55375515 Dose Level 5","genericName":"JNJ-55375515 Dose Level 5","slug":"jnj-55375515-dose-level-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-67835989","genericName":"JNJ-67835989","slug":"jnj-67835989","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ultram","genericName":"tramadol","slug":"tramadol","phase":"marketed","mechanism":"Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor","indications":["Chronic pain","Osteoarthritis","Pain"],"catalyst":""},{"name":"14C-aticaprant","genericName":"14C-aticaprant","slug":"14c-aticaprant","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AL-335","genericName":"AL-335","slug":"al-335","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARV Background Regimen","genericName":"ARV Background Regimen","slug":"arv-background-regimen","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Active reference comparator","genericName":"Active reference comparator","slug":"active-reference-comparator","phase":"phase_3","mechanism":"Unable to determine specific mechanism without drug identity.","indications":[],"catalyst":""},{"name":"Canagliflozin 300 mg","genericName":"Canagliflozin 300 mg","slug":"canagliflozin-300-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Candin","genericName":"Candin","slug":"candin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cilta-cel","genericName":"Cilta-cel","slug":"cilta-cel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dara SC","genericName":"Dara SC","slug":"dara-sc","phase":"phase_3","mechanism":"Dara SC (daratumumab subcutaneous) is a monoclonal antibody that targets CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Daratumumab IV","genericName":"Daratumumab IV","slug":"daratumumab-iv","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Daratumumab SC","genericName":"Daratumumab SC","slug":"daratumumab-sc","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Darunavir/Cobicistat (FDC)","genericName":"Darunavir/Cobicistat (FDC)","slug":"darunavir-cobicistat-fdc","phase":"marketed","mechanism":"Darunavir is a protease inhibitor that blocks HIV protease to prevent viral replication, while cobicistat is a boosting agent that inhibits CYP3A4 to increase darunavir levels.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection in combination with other antiretroviral agents"],"catalyst":""},{"name":"Fentanyl matrix","genericName":"Fentanyl matrix","slug":"fentanyl-matrix","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fentanyl-TTS","genericName":"Fentanyl-TTS","slug":"fentanyl-tts","phase":"marketed","mechanism":"Fentanyl-TTS is a transdermal patch that delivers the opioid fentanyl through the skin at a controlled rate to provide long-acting pain relief.","indications":["Chronic pain in opioid-tolerant patients","Cancer pain","Severe chronic pain requiring opioid therapy"],"catalyst":""},{"name":"GSK2336805 120 mg","genericName":"GSK2336805 120 mg","slug":"gsk2336805-120-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"INI Based Regimen","genericName":"INI Based Regimen","slug":"ini-based-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-63623872 600 mg","genericName":"JNJ-63623872 600 mg","slug":"jnj-63623872-600-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-63723283","genericName":"JNJ-63723283","slug":"jnj-63723283","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNS020QD","genericName":"JNS020QD","slug":"jns020qd","phase":"phase_3","mechanism":"JNS020QD is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ODV 100 mg","genericName":"ODV 100 mg","slug":"odv-100-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ODV 25 mg","genericName":"ODV 25 mg","slug":"odv-25-mg","phase":"discontinued","mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly.","indications":["Chronic Hepatitis C (genotypes 1–6)"],"catalyst":""},{"name":"PP1M","genericName":"PP1M","slug":"pp1m","phase":"phase_3","mechanism":"PP1M is a phosphodiesterase 10 (PDE10) inhibitor that increases intracellular cyclic nucleotide levels to modulate neuronal signaling.","indications":["Schizophrenia"],"catalyst":""},{"name":"Rabeprazol","genericName":"Rabeprazol","slug":"rabeprazol","phase":"discontinued","mechanism":"Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3","indications":["Duodenal Ulcer due to H. Pylori","Duodenal ulcer disease","Gastroesophageal reflux disease","Maintenance of Healing Gastroesophageal Reflux","Multiple endocrine adenomas"],"catalyst":""},{"name":"Risperidone long acting injectables","genericName":"Risperidone long acting injectables","slug":"risperidone-long-acting-injectables","phase":"marketed","mechanism":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (maintenance treatment)","Irritability associated with autism spectrum disorder"],"catalyst":""},{"name":"Treatment C (placebo)","genericName":"Treatment C (placebo)","slug":"treatment-c-placebo","phase":"marketed","mechanism":"Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and physiological expectation.","indications":["Used as control comparator in clinical trials across all therapeutic areas"],"catalyst":""},{"name":"Ustekinumab (90 mg)","genericName":"Ustekinumab (90 mg)","slug":"ustekinumab-90-mg","phase":"phase_3","mechanism":"Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Moderate to severe Crohn's disease"],"catalyst":""},{"name":"VEN","genericName":"VEN","slug":"ven","phase":"marketed","mechanism":"Venetoclax is a selective inhibitor of the anti-apoptotic protein BCL-2 that promotes cancer cell death by restoring apoptosis.","indications":["Chronic lymphocytic leukemia (CLL), treatment-naïve and relapsed/refractory","Acute myeloid leukemia (AML), newly diagnosed in patients ≥75 years or unfit for intensive chemotherapy","Small lymphocytic lymphoma (SLL), relapsed/refractory"],"catalyst":""},{"name":"Xilonix","genericName":"Xilonix","slug":"xilonix","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"decitabine injection","genericName":"decitabine injection","slug":"decitabine-injection","phase":"marketed","mechanism":"Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells.","indications":["Myelodysplastic syndromes (MDS)","Acute myeloid leukemia (AML)"],"catalyst":""},{"name":"double blind PR OROS methylphenidate","genericName":"double blind PR OROS methylphenidate","slug":"double-blind-pr-oros-methylphenidate","phase":"phase_3","mechanism":"Methylphenidate is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"11C-JNJ-63779586","genericName":"11C-JNJ-63779586","slug":"11c-jnj-63779586","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-JNJ-56136379","genericName":"14C-JNJ-56136379","slug":"14c-jnj-56136379","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-bleximenib","genericName":"14C-bleximenib","slug":"14c-bleximenib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-lazertinib","genericName":"14C-lazertinib","slug":"14c-lazertinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"18F-JNJ-64326067","genericName":"18F-JNJ-64326067","slug":"18f-jnj-64326067","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"5-Flurouracil","genericName":"5-Flurouracil","slug":"5-flurouracil","phase":"phase_3","mechanism":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cell death.","indications":["Colorectal cancer","Breast cancer","Gastric cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"AAV5-hRKp.RPGR","genericName":"AAV5-hRKp.RPGR","slug":"aav5-hrkp-rpgr","phase":"phase_2","mechanism":"AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.","indications":["X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations"],"catalyst":""},{"name":"ARX517","genericName":"ARX517","slug":"arx517","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Abiraterone Acetate","genericName":"ABIRATERONE","slug":"chembl-chembl254328","phase":"marketed","mechanism":"Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow.","indications":["Metastatic castration-resistant prostate cancer (CRPC)","Metastatic high-risk castration-sensitive prostate cancer (CSPC)"],"catalyst":""},{"name":"Abiraterone Acetate (AA)","genericName":"Abiraterone Acetate (AA)","slug":"abiraterone-acetate-aa","phase":"phase_3","mechanism":"Abiraterone acetate inhibits CYP17A1, a key enzyme in androgen synthesis, thereby reducing testosterone production in patients with castration-resistant prostate cancer.","indications":["Metastatic castration-resistant prostate cancer (mCRPC)","High-risk castration-sensitive prostate cancer (in combination with androgen deprivation therapy)"],"catalyst":""},{"name":"Abiraterone acetate and prednisone","genericName":"Abiraterone acetate and prednisone","slug":"abiraterone-acetate-and-prednisone","phase":"phase_3","mechanism":"Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while prednisone suppresses ACTH-driven compensatory steroid production in castration-resistant prostate cancer.","indications":["Metastatic castration-resistant prostate cancer","High-risk castration-sensitive prostate cancer (in combination with androgen deprivation therapy)"],"catalyst":""},{"name":"Abiraterone: Treatment A","genericName":"Abiraterone: Treatment A","slug":"abiraterone-treatment-a","phase":"phase_1","mechanism":"Inhibits CYP17, a key enzyme in the biosynthesis of androgens.","indications":["Prostate cancer"],"catalyst":""},{"name":"Abiraterone: Treatment C","genericName":"Abiraterone: Treatment C","slug":"abiraterone-treatment-c","phase":"phase_1","mechanism":"CYP17 inhibitor","indications":["Prostate cancer"],"catalyst":""},{"name":"Abiraterone: Treatment D","genericName":"Abiraterone: Treatment D","slug":"abiraterone-treatment-d","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ad26.Filo","genericName":"Ad26.Filo","slug":"ad26-filo","phase":"phase_1","mechanism":"Ad26.Filo is a viral vector vaccine that targets filoviruses.","indications":["Ebola"],"catalyst":""},{"name":"Ad26.Mos.HIV","genericName":"Ad26.Mos.HIV","slug":"ad26-mos-hiv","phase":"phase_1","mechanism":"HIV vaccine","indications":["HIV prevention"],"catalyst":""},{"name":"Ad26.RSV.preF-based vaccine","genericName":"Ad26.RSV.preF-based vaccine","slug":"ad26-rsv-pref-based-vaccine","phase":"phase_3","mechanism":"An adenovirus serotype 26 (Ad26)-based vaccine expressing the respiratory syncytial virus (RSV) prefusion F protein to elicit immune responses against RSV infection.","indications":["Prevention of respiratory syncytial virus (RSV) infection in adults","Prevention of RSV disease in older adults (≥60 years)"],"catalyst":""},{"name":"Ad26.ZEBOV 0.8*10^10 (vp)","genericName":"Ad26.ZEBOV 0.8*10^10 (vp)","slug":"ad26-zebov-0-8-10-10-vp","phase":"phase_3","mechanism":"Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection.","indications":["Ebola virus disease prevention (Zaire ebolavirus)"],"catalyst":""},{"name":"Ad26.ZEBOV 2*10^10 (vp)","genericName":"Ad26.ZEBOV 2*10^10 (vp)","slug":"ad26-zebov-2-10-10-vp","phase":"phase_3","mechanism":"Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus.","indications":["Ebola virus disease prevention","Post-exposure prophylaxis for Ebola virus exposure"],"catalyst":""},{"name":"Ad26.ZIKV.001 1*10^11 vp","genericName":"Ad26.ZIKV.001 1*10^11 vp","slug":"ad26-zikv-001-1-10-11-vp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ad26.ZIKV.001 5*10^10 vp","genericName":"Ad26.ZIKV.001 5*10^10 vp","slug":"ad26-zikv-001-5-10-10-vp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Adalimumab (40 mg)","genericName":"Adalimumab (40 mg)","slug":"adalimumab-40-mg","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Aged RPV-LA","genericName":"Aged RPV-LA","slug":"aged-rpv-la","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Al(OH)3","genericName":"Al(OH)3","slug":"al-oh-3","phase":"phase_3","mechanism":"Aluminum hydroxide acts as an adjuvant that enhances immune response by promoting antigen presentation and activating innate immunity.","indications":["Vaccine adjuvant in phase 3 vaccine development by Janssen Vaccines & Prevention B.V."],"catalyst":""},{"name":"Ami-HC","genericName":"Ami-HC","slug":"ami-hc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ami-HC-CF","genericName":"Ami-HC-CF","slug":"ami-hc-cf","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ami-LC","genericName":"Ami-LC","slug":"ami-lc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amivantamab IV","genericName":"Amivantamab IV","slug":"amivantamab-iv","phase":"phase_2","mechanism":"Targeting EGFR","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Amivantamab Intravenous","genericName":"Amivantamab Intravenous","slug":"amivantamab-intravenous","phase":"phase_3","mechanism":"Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death.","indications":["Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations","EGFR-mutant NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors"],"catalyst":""},{"name":"Amivantamab SC","genericName":"Amivantamab SC","slug":"amivantamab-sc","phase":"phase_2","mechanism":"Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors.","indications":["Metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation","Locally advanced or metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation"],"catalyst":""},{"name":"Anti TNF therapy including infliximab","genericName":"Anti TNF therapy including infliximab","slug":"anti-tnf-therapy-including-infliximab","phase":"phase_2","mechanism":"Blocks tumor necrosis factor-alpha (TNF-alpha) by binding to it and preventing it from interacting with cell surface TNF receptors.","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ulcerative Colitis","Crohn's Disease"],"catalyst":""},{"name":"Antidepressant","genericName":"Antidepressant","slug":"antidepressant","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antihyperglycemic agent(s)","genericName":"Antihyperglycemic agent(s)","slug":"antihyperglycemic-agent-s","phase":"phase_3","mechanism":"Antihyperglycemic agents work by reducing blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Apixaban 2.5 mg","genericName":"Apixaban 2.5 mg","slug":"apixaban-2-5-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aticaprant Therapeutic Dose","genericName":"Aticaprant Therapeutic Dose","slug":"aticaprant-therapeutic-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atomoxetine (ATO)","genericName":"Atomoxetine (ATO)","slug":"atomoxetine-ato","phase":"marketed","mechanism":"Atomoxetine selectively inhibits the reuptake of norepinephrine in the central nervous system, increasing norepinephrine availability at synapses.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults","ADHD-related symptoms in patients with comorbid conditions"],"catalyst":""},{"name":"BCG Vesiculture","genericName":"BCG Vesiculture","slug":"bcg-vesiculture","phase":"phase_3","mechanism":"BCG Vesiculture is a live attenuated Bacillus Calmette-Guérin vaccine formulation designed to stimulate innate and adaptive immune responses against bladder cancer.","indications":["Non-muscle invasive bladder cancer (NMIBC), high-grade urothelial carcinoma"],"catalyst":""},{"name":"Bermekimab Monoclonal Antibody","genericName":"Bermekimab Monoclonal Antibody","slug":"bermekimab-monoclonal-antibody","phase":"phase_2","mechanism":"Bermekimab is a monoclonal antibody that blocks IL-1β, a key pro-inflammatory cytokine, to reduce inflammation and immune activation.","indications":["Inflammatory conditions (Phase 2 development)"],"catalyst":""},{"name":"Best Supportive Care (BSC)","genericName":"Best Supportive Care (BSC)","slug":"best-supportive-care-bsc","phase":"phase_3","mechanism":"Best Supportive Care (BSC) is a control or comparator arm in clinical trials that provides standard medical management and symptom relief without the investigational drug.","indications":[],"catalyst":""},{"name":"Bridging Therapy","genericName":"Bridging Therapy","slug":"bridging-therapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CNTO 148","genericName":"CNTO 148","slug":"cnto-148","phase":"phase_3","mechanism":"CNTO 148 is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in immune-mediated diseases.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"CNTO 1959","genericName":"CNTO 1959","slug":"cnto-1959","phase":"phase_2","mechanism":"CNTO 1959 is a monoclonal antibody that inhibits IL-23 signaling to reduce inflammatory immune responses.","indications":["Psoriasis","Inflammatory bowel disease"],"catalyst":""},{"name":"Canagliflozin tablets","genericName":"Canagliflozin tablets","slug":"canagliflozin-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Canagliflozin, 100 mg","genericName":"Canagliflozin, 100 mg","slug":"canagliflozin-100-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cilta-cel OOS Therapy","genericName":"Cilta-cel OOS Therapy","slug":"cilta-cel-oos-therapy","phase":"phase_2","mechanism":"Chimeric antigen receptor T-cell therapy","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Concerta AG formulation","genericName":"Concerta AG formulation","slug":"concerta-ag-formulation","phase":"phase_2","mechanism":"Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.","indications":["Attention Deficit Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"Concerta EG formulation","genericName":"Concerta EG formulation","slug":"concerta-eg-formulation","phase":"phase_2","mechanism":"Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.","indications":["Attention Deficit Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"Cosentyx","genericName":"Cosentyx","slug":"cosentyx","phase":"marketed","mechanism":"Interleukin-17A","indications":["Ankylosing spondylitis","Non-radiographic axial spondyloarthritis","Plaque psoriasis","Psoriatic arthritis","Pustular psoriasis"],"catalyst":""},{"name":"DRV/COBI FDC","genericName":"DRV/COBI FDC","slug":"drv-cobi-fdc","phase":"phase_3","mechanism":"DRV/COBI is a fixed-dose combination of darunavir (a protease inhibitor) and cobicistat (a pharmacokinetic booster) that inhibits HIV protease to prevent viral replication.","indications":["HIV-1 infection in treatment-naive and treatment-experienced patients"],"catalyst":""},{"name":"Dapoxetine hydrochloride","genericName":"Dapoxetine hydrochloride","slug":"dapoxetine-hydrochloride","phase":"phase_3","mechanism":"Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the central nervous system to delay ejaculation.","indications":["Premature ejaculation in men aged 18-64 years"],"catalyst":""},{"name":"Dara IV","genericName":"Dara IV","slug":"dara-iv","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Daratumumab SC: daratumumab + rHuPH20","genericName":"Daratumumab SC: daratumumab + rHuPH20","slug":"daratumumab-sc-daratumumab-rhuph20","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while rHuPH20 enhances subcutaneous bioavailability.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Darunavir/Ritonavir (DRV/r)","genericName":"Darunavir/Ritonavir (DRV/r)","slug":"darunavir-ritonavir-drv-r","phase":"phase_3","mechanism":"Darunavir is a protease inhibitor that blocks HIV protease, preventing viral polyprotein cleavage and maturation, while ritonavir acts as a pharmacokinetic booster to increase darunavir levels.","indications":["HIV-1 infection in treatment-experienced patients","HIV-1 infection in treatment-naïve patients"],"catalyst":""},{"name":"Dexamethasone 20 mg","genericName":"Dexamethasone 20 mg","slug":"dexamethasone-20-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Efavirenz (EFV)","genericName":"Efavirenz (EFV)","slug":"efavirenz-efv","phase":"marketed","mechanism":"Efavirenz inhibits HIV reverse transcriptase, blocking the enzyme that converts viral RNA into DNA and preventing HIV replication.","indications":["HIV-1 infection (in combination with other antiretroviral agents)"],"catalyst":""},{"name":"Epo-alpha","genericName":"Epo-alpha","slug":"epo-alpha","phase":"phase_3","mechanism":"Epo-alpha is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in cancer patients receiving chemotherapy","Anemia in patients with HIV infection"],"catalyst":""},{"name":"Erdafitinib Intravesical Delivery System","genericName":"Erdafitinib Intravesical Delivery System","slug":"erdafitinib-intravesical-delivery-system","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Esketamine 56 mg","genericName":"Esketamine 56 mg","slug":"esketamine-56-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ExPEC9V","genericName":"ExPEC9V","slug":"expec9v","phase":"phase_3","mechanism":"ExPEC9V is a vaccine designed to stimulate immune responses against extraintestinal pathogenic E. coli (ExPEC) strains.","indications":["Prevention of urinary tract infections caused by ExPEC","Prevention of bacteremia and invasive infections caused by ExPEC"],"catalyst":""},{"name":"FTC/TDF FDC","genericName":"FTC/TDF FDC","slug":"ftc-tdf-fdc","phase":"phase_3","mechanism":"FTC/TDF is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection (treatment)","HIV-1 pre-exposure prophylaxis (PrEP)"],"catalyst":""},{"name":"Fentanyl D-trans","genericName":"Fentanyl D-trans","slug":"fentanyl-d-trans","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fentanyl ITS","genericName":"Fentanyl ITS","slug":"fentanyl-its","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Galantamine (Reminyl)","genericName":"Galantamine (Reminyl)","slug":"galantamine-reminyl","phase":"marketed","mechanism":"Galantamine inhibits acetylcholinesterase to increase acetylcholine levels in the brain, and also acts as an allosteric modulator of nicotinic receptors to enhance cholinergic neurotransmission.","indications":["Mild to moderate Alzheimer's disease"],"catalyst":""},{"name":"Genetic: AAV5-hRKp.RPGR","genericName":"Genetic: AAV5-hRKp.RPGR","slug":"genetic-aav5-hrkp-rpgr","phase":"phase_3","mechanism":"AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.","indications":["X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations"],"catalyst":""},{"name":"Genetic: AAV5-hRKp.RPGR Intermediate Dose","genericName":"Genetic: AAV5-hRKp.RPGR Intermediate Dose","slug":"genetic-aav5-hrkp-rpgr-intermediate-dose","phase":"phase_3","mechanism":"AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.","indications":["X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations"],"catalyst":""},{"name":"Genetic: AAV5-hRKp.RPGR Low Dose","genericName":"Genetic: AAV5-hRKp.RPGR Low Dose","slug":"genetic-aav5-hrkp-rpgr-low-dose","phase":"phase_3","mechanism":"AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.","indications":["X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations"],"catalyst":""},{"name":"Guselkumab Dose 1","genericName":"Guselkumab Dose 1","slug":"guselkumab-dose-1","phase":"phase_3","mechanism":"Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Crohn's disease"],"catalyst":""},{"name":"Guselkumab Intravenous","genericName":"Guselkumab Intravenous","slug":"guselkumab-intravenous","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Guselkumab Subcutaneous","genericName":"Guselkumab Subcutaneous","slug":"guselkumab-subcutaneous","phase":"phase_3","mechanism":"Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Crohn's disease"],"catalyst":""},{"name":"Gynoclin V","genericName":"Gynoclin V","slug":"gynoclin-v","phase":"phase_3","mechanism":"Gynoclin V is a clindamycin-based vaginal formulation that inhibits bacterial protein synthesis to treat vaginal infections.","indications":["Bacterial vaginosis","Vaginal infections caused by susceptible bacteria"],"catalyst":""},{"name":"HD quadrivalent influenza vaccine","genericName":"HD quadrivalent influenza vaccine","slug":"hd-quadrivalent-influenza-vaccine","phase":"phase_3","mechanism":"HD quadrivalent influenza vaccine stimulates immune responses against four strains of influenza virus using a high-dose antigen formulation to enhance protection, particularly in older adults.","indications":["Prevention of influenza in adults aged 65 years and older","Prevention of influenza in adults aged 18 years and older (Phase 3 evaluation)"],"catalyst":""},{"name":"Hydromorphone HCl OROS","genericName":"Hydromorphone HCl OROS","slug":"hydromorphone-hcl-oros","phase":"marketed","mechanism":"Hydromorphone HCl OROS is an opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and is formulated as an extended-release osmotic system for sustained pain relief.","indications":["Moderate to severe chronic pain requiring around-the-clock opioid therapy"],"catalyst":""},{"name":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","slug":"itcz-oral-solution","phase":"phase_3","mechanism":"ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Oropharyngeal candidiasis","Esophageal candidiasis","Systemic fungal infections (aspergillosis, blastomycosis, histoplasmosis, cryptococcosis)"],"catalyst":""},{"name":"ITCZ-IV","genericName":"ITCZ-IV","slug":"itcz-iv","phase":"phase_3","mechanism":"ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Invasive aspergillosis","Blastomycosis","Histoplasmosis","Cryptococcosis"],"catalyst":""},{"name":"Imaavy","genericName":"NIPOCALIMAB","slug":"nipocalimab","phase":"marketed","mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG.","indications":["Generalized Myasthenia Gravis (gMG)"],"catalyst":""},{"name":"Imvanex","genericName":"Imvanex","slug":"imvanex","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Intelence","genericName":"ETRAVIRINE","slug":"etravirine","phase":"marketed","mechanism":"Intelence works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Intravenous Esketamine","genericName":"Intravenous Esketamine","slug":"intravenous-esketamine","phase":"marketed","mechanism":"Intravenous esketamine is an NMDA receptor antagonist that rapidly blocks glutamate signaling in the brain to produce fast-acting antidepressant effects.","indications":["Treatment-resistant depression (TRD)","Major depressive disorder with acute suicidal ideation or behavior"],"catalyst":""},{"name":"JNJ-42756493: Part 1","genericName":"JNJ-42756493: Part 1","slug":"jnj-42756493-part-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-54861911","genericName":"JNJ-54861911","slug":"jnj-54861911","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-54861911, 50 mg","genericName":"JNJ-54861911, 50 mg","slug":"jnj-54861911-50-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-54861911-Therapeutic Dose","genericName":"JNJ-54861911-Therapeutic Dose","slug":"jnj-54861911-therapeutic-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-55308942 High Dose","genericName":"JNJ-55308942 High Dose","slug":"jnj-55308942-high-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-56021927 240 Milligram","genericName":"JNJ-56021927 240 Milligram","slug":"jnj-56021927-240-milligram","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-61393215","genericName":"JNJ-61393215","slug":"jnj-61393215","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64042056","genericName":"JNJ-64042056","slug":"jnj-64042056","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64565111 Dose Level 1","genericName":"JNJ-64565111 Dose Level 1","slug":"jnj-64565111-dose-level-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64565111 Dose Level 2","genericName":"JNJ-64565111 Dose Level 2","slug":"jnj-64565111-dose-level-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64565111 Dose Level 3","genericName":"JNJ-64565111 Dose Level 3","slug":"jnj-64565111-dose-level-3","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64991524 Dose Level 8","genericName":"JNJ-64991524 Dose Level 8","slug":"jnj-64991524-dose-level-8","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-67571244","genericName":"JNJ-67571244","slug":"jnj-67571244","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-67953964","genericName":"JNJ-67953964","slug":"jnj-67953964","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-68284528","genericName":"JNJ-68284528","slug":"jnj-68284528","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-77242113","genericName":"JNJ-77242113","slug":"jnj-77242113","phase":"phase_3","mechanism":"JNJ-77242113 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain to modulate neuronal activity.","indications":["Schizophrenia","Bipolar disorder (exploratory)"],"catalyst":""},{"name":"JNJ-78934804","genericName":"JNJ-78934804","slug":"jnj-78934804","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"JNJ-79635322","genericName":"JNJ-79635322","slug":"jnj-79635322","phase":"phase_3","mechanism":"JNJ-79635322 is a monoclonal antibody that targets and inhibits IL-17A, a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.","indications":["Psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"JNJ-95475939","genericName":"JNJ-95475939","slug":"jnj-95475939","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNS001","genericName":"JNS001","slug":"jns001","phase":"phase_3","mechanism":"JNS001 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.","indications":[],"catalyst":""},{"name":"Ketoconazole 200 mg","genericName":"Ketoconazole 200 mg","slug":"ketoconazole-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Leucovorin calcium/Levoleucovorin","genericName":"Leucovorin calcium/Levoleucovorin","slug":"leucovorin-calcium-levoleucovorin","phase":"phase_3","mechanism":"Leucovorin calcium and levoleucovorin are reduced folate cofactors that enhance the efficacy of antimetabolite chemotherapy agents by providing essential one-carbon units for nucleotide synthesis.","indications":["Metastatic colorectal cancer (in combination with fluorouracil)","High-dose methotrexate toxicity rescue","Fluorouracil-based chemotherapy potentiation"],"catalyst":""},{"name":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","genericName":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","slug":"mva-bn-filo-1-10-8-infectious-unit-inf-u","phase":"phase_3","mechanism":"MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.","indications":["Prevention of Ebola virus disease","Prevention of Marburg virus disease"],"catalyst":""},{"name":"MVA-BN-Filo 5*10^7 Inf. U.","genericName":"MVA-BN-Filo 5*10^7 Inf. U.","slug":"mva-bn-filo-5-10-7-inf-u","phase":"phase_3","mechanism":"MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.","indications":["Prevention of Ebola virus disease","Prevention of Marburg virus disease"],"catalyst":""},{"name":"Matching Placebo to JNJ-77242113","genericName":"Matching Placebo to JNJ-77242113","slug":"matching-placebo-to-jnj-77242113","phase":"phase_3","mechanism":"This is a placebo control formulation matching the inactive vehicle and appearance of JNJ-77242113 for blinded clinical trial comparison.","indications":[],"catalyst":""},{"name":"Matching Placebo to Ustekinumab","genericName":"Matching Placebo to Ustekinumab","slug":"matching-placebo-to-ustekinumab","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration route of ustekinumab for blinded clinical trial comparison.","indications":[],"catalyst":""},{"name":"Matching placebo to Quetiapine XR","genericName":"Matching placebo to Quetiapine XR","slug":"matching-placebo-to-quetiapine-xr","phase":"phase_3","mechanism":"This is a matching placebo formulation designed to mimic Quetiapine XR (an atypical antipsychotic) for blinded clinical trial purposes.","indications":["Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial)"],"catalyst":""},{"name":"Matching placebo to Seltorexant","genericName":"Matching placebo to Seltorexant","slug":"matching-placebo-to-seltorexant","phase":"phase_3","mechanism":"This is a matching placebo control formulation designed to mimic Seltorexant, an orexin 2 receptor antagonist used in sleep disorder trials.","indications":["Matching placebo control for Seltorexant clinical trials (not a therapeutic agent)"],"catalyst":""},{"name":"Metformin immediate release","genericName":"Metformin immediate release","slug":"metformin-immediate-release","phase":"phase_3","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.","indications":["Type 2 diabetes mellitus","Prediabetes (prevention of progression to type 2 diabetes)"],"catalyst":""},{"name":"Miconazole plus Hydrocortisone","genericName":"Miconazole plus Hydrocortisone","slug":"miconazole-plus-hydrocortisone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nipocalimab SC-LIV","genericName":"Nipocalimab SC-LIV","slug":"nipocalimab-sc-liv","phase":"phase_3","mechanism":"Nipocalimab is a subcutaneous monoclonal antibody that blocks neonatal Fc receptor (FcRn) to reduce pathogenic immunoglobulin levels in autoimmune conditions.","indications":["Generalized myasthenia gravis (gMG)","IgG-mediated autoimmune conditions"],"catalyst":""},{"name":"Nucynta ER","genericName":"Nucynta ER","slug":"nucynta-er","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OROS hydromorphone HCl","genericName":"OROS hydromorphone HCl","slug":"oros-hydromorphone-hcl","phase":"marketed","mechanism":"OROS hydromorphone HCl is an extended-release opioid agonist that binds to mu-opioid receptors in the central nervous system to provide sustained pain relief.","indications":["Moderate to severe chronic pain requiring continuous opioid therapy"],"catalyst":""},{"name":"Odalasvir 25 mg","genericName":"Odalasvir 25 mg","slug":"odalasvir-25-mg","phase":"discontinued","mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly.","indications":["Chronic hepatitis C virus infection (genotypes 1–6)"],"catalyst":""},{"name":"Odalasvir 75 mg","genericName":"Odalasvir 75 mg","slug":"odalasvir-75-mg","phase":"discontinued","mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly.","indications":["Chronic hepatitis C (genotype 1)","Chronic hepatitis C (treatment-naïve and treatment-experienced)","Chronic hepatitis C (Japanese population)"],"catalyst":""},{"name":"Oxybutinin Extended-Release","genericName":"Oxybutinin Extended-Release","slug":"oxybutinin-extended-release","phase":"marketed","mechanism":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","indications":["Overactive bladder with symptoms of urge incontinence, urgency, and frequency","Neurogenic detrusor overactivity in spinal cord injury patients"],"catalyst":""},{"name":"Oxybutynin chloride OROS","genericName":"Oxybutynin chloride OROS","slug":"oxybutynin-chloride-oros","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PCI-32765 (Ibrutinib)","genericName":"PCI-32765 (Ibrutinib)","slug":"pci-32765-ibrutinib","phase":"phase_3","mechanism":"Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell receptor signaling and reduces proliferation of malignant B cells.","indications":["Chronic lymphocytic leukemia (CLL)","Mantle cell lymphoma (MCL)","Marginal zone lymphoma (MZL)","Waldenstrom macroglobulinemia (WM)"],"catalyst":""},{"name":"PP6M injection Dose 1","genericName":"PP6M injection Dose 1","slug":"pp6m-injection-dose-1","phase":"phase_3","mechanism":"PP6M is a long-acting injectable contraceptive that prevents pregnancy through hormonal suppression of ovulation.","indications":["Contraception in women of reproductive age"],"catalyst":""},{"name":"Paliperdidone ER","genericName":"Paliperdidone ER","slug":"paliperdidone-er","phase":"marketed","mechanism":"Paliperidone ER is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms.","indications":["Schizophrenia","Schizoaffective disorder","Bipolar I disorder (acute and maintenance treatment)"],"catalyst":""},{"name":"Placebo (20% Intralipid)","genericName":"Placebo (20% Intralipid)","slug":"placebo-20-intralipid","phase":"phase_3","mechanism":"Placebo (20% Intralipid) does not have an active pharmacological effect; it serves as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo A (After CP)","genericName":"Placebo A (After CP)","slug":"placebo-a-after-cp","phase":"phase_3","mechanism":"Placebo A is an inert control substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo B (After CP)","genericName":"Placebo B (After CP)","slug":"placebo-b-after-cp","phase":"phase_3","mechanism":"Placebo B is an inert control substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo and prednisone","genericName":"Placebo and prednisone","slug":"placebo-and-prednisone","phase":"phase_3","mechanism":"This is a comparator arm combining placebo with prednisone, a corticosteroid that suppresses immune function and reduces inflammation.","indications":["Active comparator arm in phase 3 clinical trial (specific indication unknown)"],"catalyst":""},{"name":"Placebo for Adalimumab","genericName":"Placebo for Adalimumab","slug":"placebo-for-adalimumab","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for adalimumab (TNF-alpha inhibitor)"],"catalyst":""},{"name":"Placebo for Niraparib","genericName":"Placebo for Niraparib","slug":"placebo-for-niraparib","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for Niraparib"],"catalyst":""},{"name":"Placebo for Ustekinumab","genericName":"Placebo for Ustekinumab","slug":"placebo-for-ustekinumab","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial of ustekinumab (active comparator)"],"catalyst":""},{"name":"Placebo for guselkumab","genericName":"Placebo for guselkumab","slug":"placebo-for-guselkumab","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":[],"catalyst":""},{"name":"Prezista","genericName":"DARUNAVIR","slug":"darunavir","phase":"marketed","mechanism":"Darunavir works by blocking the protease enzyme, which is essential for the replication of the HIV virus.","indications":["Human immunodeficiency virus infection"],"catalyst":""},{"name":"Propranolol booster","genericName":"Propranolol booster","slug":"propranolol-booster","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Quadrivalent High-dose Influenza Vaccine","genericName":"Quadrivalent High-dose Influenza Vaccine","slug":"quadrivalent-high-dose-influenza-vaccine","phase":"phase_3","mechanism":"This vaccine induces an immune response against multiple influenza strains.","indications":["Prevention of influenza disease in adults 65 years of age and older"],"catalyst":""},{"name":"RSV preF Protein 50 mcg","genericName":"RSV preF Protein 50 mcg","slug":"rsv-pref-protein-50-mcg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"RYBREVANT","genericName":"AMIVANTAMAB-VMJW","slug":"amivantamab-vmjw","phase":"marketed","mechanism":"Epidermal growth factor receptor, Hepatocyte growth factor receptor","indications":["Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations"],"catalyst":""},{"name":"Rilpivirine (RPV)","genericName":"Rilpivirine (RPV)","slug":"rilpivirine-rpv","phase":"phase_3","mechanism":"Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the replication of HIV-1 by binding to the reverse transcriptase enzyme.","indications":["Treatment of HIV-1 infection in treatment-naive adults"],"catalyst":""},{"name":"Rilpivirine formulation G009-01","genericName":"Rilpivirine formulation G009-01","slug":"rilpivirine-formulation-g009-01","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Risperidone Long acting injectable","genericName":"Risperidone Long acting injectable","slug":"risperidone-long-acting-injectable","phase":"marketed","mechanism":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (maintenance treatment)","Irritability associated with autism spectrum disorder","Aggression and behavioral disturbances in patients with psychotic disorders"],"catalyst":""},{"name":"Risperidone prolonged release","genericName":"Risperidone prolonged release","slug":"risperidone-prolonged-release","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Standard of Care Treatment","genericName":"Standard of Care Treatment","slug":"standard-of-care-treatment","phase":"phase_3","mechanism":"This drug works by inhibiting the PD-1 receptor, which helps the immune system recognize and attack cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma","Urothelial carcinoma","Melanoma","Renal cell carcinoma"],"catalyst":""},{"name":"Sulfonylureas (SU)","genericName":"Sulfonylureas (SU)","slug":"sulfonylureas-su","phase":"phase_3","mechanism":"Sulfonylureas stimulate insulin release from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Sulphonylruea","genericName":"Sulphonylruea","slug":"sulphonylruea","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sulphonylurea","genericName":"Sulphonylurea","slug":"sulphonylurea","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TAF/FTC FDC","genericName":"TAF/FTC FDC","slug":"taf-ftc-fdc","phase":"marketed","mechanism":"TAF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"],"catalyst":""},{"name":"TALVEY","genericName":"TALQUETAMAB-TGVS","slug":"talquetamab-tgvs","phase":"marketed","mechanism":"G-protein coupled receptor family C group 5 member D, T-cell surface glycoprotein CD3","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"TAR-200","genericName":"TAR-200","slug":"tar-200","phase":"phase_3","mechanism":"TAR-200 is a monoclonal antibody targeting the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""},{"name":"TAR-210","genericName":"TAR-210","slug":"tar-210","phase":"phase_3","mechanism":"TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"TECVAYLI","genericName":"TECLISTAMAB-CQYV","slug":"teclistamab-cqyv","phase":"marketed","mechanism":"Tumor necrosis factor receptor superfamily member 17, T-cell surface glycoprotein CD3","indications":["Relapsed or Refractory Multiple Myeloma (Combination Therapy)","Relapsed or Refractory Multiple Myeloma (Monotherapy)"],"catalyst":""},{"name":"TMC114/ritonavir","genericName":"TMC114/ritonavir","slug":"tmc114-ritonavir","phase":"marketed","mechanism":"TMC114 (darunavir) is a protease inhibitor that blocks HIV protease, preventing viral replication when boosted with ritonavir.","indications":["HIV-1 infection in treatment-experienced patients","HIV-1 infection in treatment-naïve patients"],"catalyst":""},{"name":"TTS-fentanyl","genericName":"TTS-fentanyl","slug":"tts-fentanyl","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TVR","genericName":"TVR","slug":"tvr","phase":"phase_3","mechanism":"TVR is a protease inhibitor that works by blocking the replication of the hepatitis C virus.","indications":["Chronic hepatitis C","Hepatitis C genotype 1 infection"],"catalyst":""},{"name":"Tacrolimus With Diet and Exercise Intervention","genericName":"Tacrolimus With Diet and Exercise Intervention","slug":"tacrolimus-with-diet-and-exercise-intervention","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topamax","genericName":"topiramate","slug":"topiramate","phase":"marketed","mechanism":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","indications":["Epilepsy characterized by intractable complex partial seizures","Lennox-Gastaut syndrome","Migraine Prevention","Simple partial seizure","Tonic-clonic epilepsy"],"catalyst":""},{"name":"Topiramate Slow","genericName":"Topiramate Slow","slug":"topiramate-slow","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topiramate Standard","genericName":"Topiramate Standard","slug":"topiramate-standard","phase":"marketed","mechanism":"Topiramate blocks sodium channels and enhances GABA-mediated inhibition in the central nervous system to reduce neuronal excitability.","indications":["Epilepsy / seizure disorders","Migraine prophylaxis","Bipolar disorder (off-label)"],"catalyst":""},{"name":"Tramadol HCI/acetaminophen","genericName":"Tramadol HCI/acetaminophen","slug":"tramadol-hci-acetaminophen","phase":"marketed","mechanism":"Tramadol inhibits norepinephrine and serotonin reuptake while weakly binding opioid receptors, while acetaminophen inhibits prostaglandin synthesis to provide combined analgesic and antipyretic effects.","indications":["Moderate to moderately severe pain"],"catalyst":""},{"name":"Tramadol HCl, 50 mg","genericName":"Tramadol HCl, 50 mg","slug":"tramadol-hcl-50-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tramadol HCl/Acetaminophen IR","genericName":"Tramadol HCl/Acetaminophen IR","slug":"tramadol-hcl-acetaminophen-ir","phase":"phase_3","mechanism":"Tramadol HCl/Acetaminophen IR is a combination of a centrally acting opioid analgesic and a non-opioid analgesic that works by affecting the central nervous system to relieve pain.","indications":["Moderate to moderately severe pain","Severe pain"],"catalyst":""},{"name":"Tramadol HCl/acetaminophen Extended Release","genericName":"Tramadol HCl/acetaminophen Extended Release","slug":"tramadol-hcl-acetaminophen-extended-release","phase":"marketed","mechanism":"Tramadol inhibits norepinephrine and serotonin reuptake while acting as a weak opioid agonist, and acetaminophen reduces pain through central analgesic and antipyretic effects.","indications":["Moderate to moderately severe pain (chronic pain management)"],"catalyst":""},{"name":"Tramadol Hydrochloride Plus Acetaminophen","genericName":"Tramadol Hydrochloride Plus Acetaminophen","slug":"tramadol-hydrochloride-plus-acetaminophen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tramadol hydrochloride/ Acetaminophen","genericName":"Tramadol hydrochloride/ Acetaminophen","slug":"tramadol-hydrochloride-acetaminophen","phase":"marketed","mechanism":"Tramadol inhibits norepinephrine and serotonin reuptake while acting as a weak opioid agonist, and acetaminophen reduces pain through central analgesic and antipyretic effects.","indications":["Moderate pain"],"catalyst":""},{"name":"Treatment C: abiraterone acetate","genericName":"Treatment C: abiraterone acetate","slug":"treatment-c-abiraterone-acetate","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Treatment sequence 2","genericName":"Treatment sequence 2","slug":"treatment-sequence-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ustekinumab - Half-Standard Dosage","genericName":"Ustekinumab - Half-Standard Dosage","slug":"ustekinumab-half-standard-dosage","phase":"phase_3","mechanism":"Ustekinumab is a monoclonal antibody that blocks the action of interleukin-12 and interleukin-23, which are proteins involved in inflammation.","indications":["Moderate to severe plaque psoriasis","Moderate to severe Crohn's disease"],"catalyst":""},{"name":"Ustekinumab IV","genericName":"Ustekinumab IV","slug":"ustekinumab-iv","phase":"phase_3","mechanism":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of immune-mediated inflammatory responses.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Ustekinumab SC","genericName":"Ustekinumab SC","slug":"ustekinumab-sc","phase":"phase_3","mechanism":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of immune-mediated inflammatory responses.","indications":["Plaque psoriasis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Vagitrol V","genericName":"Vagitrol V","slug":"vagitrol-v","phase":"phase_3","mechanism":"Vagitrol V is a medication that works by inhibiting the action of a specific enzyme.","indications":["Gastroesophageal reflux disease (GERD)","Erosive esophagitis"],"catalyst":""},{"name":"Yondelis","genericName":"TRABECTEDIN","slug":"trabectedin","phase":"marketed","mechanism":"Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth.","indications":["Leiomyosarcoma","Liposarcoma","Malignant tumor of ovary","Soft or Connective Tissue Sarcoma"],"catalyst":""},{"name":"[18F]MNI-1020","genericName":"[18F]MNI-1020","slug":"18f-mni-1020","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"antipsychotics","genericName":"antipsychotics","slug":"antipsychotics","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"aspirin (ASA)","genericName":"aspirin (ASA)","slug":"aspirin-asa","phase":"marketed","mechanism":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.","indications":["Acute myocardial infarction","Secondary prevention of myocardial infarction and stroke","Unstable angina","Transient ischemic attack (TIA) prevention","Mild to moderate pain and fever"],"catalyst":""},{"name":"darunavir (DRV, TMC114)","genericName":"darunavir (DRV, TMC114)","slug":"darunavir-drv-tmc114","phase":"phase_3","mechanism":"Darunavir is a protease inhibitor that blocks the protease enzyme in HIV, preventing viral replication.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of HIV-1 infection in adults and children"],"catalyst":""},{"name":"early initiation of treatment with Risperdal Consta","genericName":"early initiation of treatment with Risperdal Consta","slug":"early-initiation-of-treatment-with-risperdal-consta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"epoetin alfa + packed RBC transfusion","genericName":"epoetin alfa + packed RBC transfusion","slug":"epoetin-alfa-packed-rbc-transfusion","phase":"phase_3","mechanism":"Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor, promoting the production of red blood cells.","indications":["Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia"],"catalyst":""},{"name":"haloperidole","genericName":"haloperidole","slug":"haloperidole","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"open label PR OROS methylphenidate","genericName":"open label PR OROS methylphenidate","slug":"open-label-pr-oros-methylphenidate","phase":"phase_3","mechanism":"Methylphenidate is a central nervous system stimulant that works by increasing the levels of dopamine and norepinephrine in the brain.","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"routine initiation of treatment with Risperdal Consta","genericName":"routine initiation of treatment with Risperdal Consta","slug":"routine-initiation-of-treatment-with-risperdal-consta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"topiramate; almotriptan malate","genericName":"topiramate; almotriptan malate","slug":"topiramate-almotriptan-malate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPdG1Dcjl0Rk9iejNVMC1UQ2VoM1RuTzh1cm82b2Q3TW1ST2JVMXRUM1JpYjNGYWp3bm5jR0VsRmZSZlJYZU5xME5RclVuU0FKcWlrVlhTV3YwOFhjdnJ1RXZoQ1dmanhocGNSaGdFUThhSnZpTG9OdEVsNlNJX2U0elZ3RURLSHM3TUE?oc=5","date":"2026-01-22","type":"pipeline","source":"Manhattan Institute","summary":"Amicus Brief: Janssen Pharmaceuticals v. Kennedy - Manhattan Institute","headline":"Amicus Brief: Janssen Pharmaceuticals v. Kennedy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQbHFuMTFKc0Zpd29fXzZiQ0JVc2ViRGYxM2V4RnU3VmdrTlFkdEdNdlZzX2pJX2RkZ2h2ZkxCOF91NEgwd21zWVlTNUpPX3ZGSnlQdnVIbUl2X3dIcWdOTE1NczYzTjItSUVhTmExcVRjWHg0WE9jenN4ZVJRQmZhYW1QeUlzQVRkeFhWY2tDcjZ5VlNOSGxuUkFNS1dsY0RJdXpFZEEzal8zNmdjT0pMV0Q4Wi16czJLM1BjcUtJYzZFTXZzVUhJTVpqTjBpVVhXRndGamE2NA?oc=5","date":"2025-12-17","type":"patent","source":"Pearce IP","summary":"Federal Court of Australia Awards Janssen First Pharmaceutical Patent Preliminary Injunction in 7 Years - Pearce IP","headline":"Federal Court of Australia Awards Janssen First Pharmaceutical Patent Preliminary Injunction in 7 Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOY2Ewc09mVzF5V29uUFdUemJUTFB1RUw3RE5KbU91M3Z2WUhBTXhWLTA5US0wV2JUSl82REpDUHpMN3dwaXBmXzRCRXlPOTlnZWUxMEo1QlNDcC1DTm51czJqVWtaVVRkNlNhbk5yRjRYMW41MzUxTG5jY0x6X1o2dzJDdVdUOHFpbzJpcEFMUHJtVnVEZFBrOXl0TdIBVkFVX3lxTE1pbXpVNjZUbTdEbUxsUWJoNDB3YnpUcGRiSkhXVVd4MFducktYY2FNdHo1YXNRYW14RWEwRzNhRV94T2tFQXRKRzNqVmg2alVvYkZlcFJR?oc=5","date":"2025-11-24","type":"patent","source":"Law360","summary":"Advanz Challenges Janssen Patents On Schizophrenia Drug - Law360","headline":"Advanz Challenges Janssen Patents On Schizophrenia Drug - Law360","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-01","type":"patent","source":"The Hindu","summary":"Lupin launches generic of Janssen Pharma’s VTE drug in U.S. - The Hindu","headline":"Lupin launches generic of Janssen Pharma’s VTE drug in U.S.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPRzZ3bExyVURvSnNsQzJtWnZma1h0cmZBMTVWZ09nXzJOaWJFS2NIOEx1eDJoYnZNMXE3VksyTTl6MXdHbU1uMS1lTmtqTDZyLWFzMTM3RmUzR2tqZEJGc3ZJUUotbEpMejg5RG5yV3RvNEMyM1hrd09nMVU2dUp1RVRqRm5Ha3p3R2tVeFdQcXRLSzY0ZlZIM3FDRnEwUjAtVzZQWXh2a2xGdw?oc=5","date":"2024-05-01","type":"pipeline","source":"Pharmaceutical Technology","summary":"Janssen adopts J&J name as part of global rebranding effort - Pharmaceutical Technology","headline":"Janssen adopts J&J name as part of global rebranding effort","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOOTcxRUt6T19GbHNEVXE4c0NkRFhaZHZWNFRKbXFNZUxPWlNZT1NKbHNLdnBHYmplLXkxcTItSTBXWEFfWTdZQkxmQXdESnJGSm93RHVyQXg2Sko1aHJuWWpseEhhU2dNNktrVExSWVJUN2FMMEJlMXVuaUlTWkl6WlBfc0h6WUVZOFlMNWsxdTNfc1lUYl9kSkY2OURtMnpj?oc=5","date":"2023-09-15","type":"trial","source":"BioPharma Dive","summary":"J&J to phase out Janssen name in corporate rebrand - BioPharma Dive","headline":"J&J to phase out Janssen name in corporate rebrand","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-04-18","type":"pipeline","source":"PBS","summary":"Johnson & Johnson subsidiary settles West Virginia opioid lawsuit for $99 million - PBS","headline":"Johnson & Johnson subsidiary settles West Virginia opioid lawsuit for $99 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNZ0NaQVZSOFhrM2pCSURRTkFTUWJrbjhPdVptS0UyQlM0N29yZGlhR3I5UlFma0JnSGdOV1pZNmYweXNiMFZ2OWkxRWt2M1ZyN3NiOHNOVjY2V0MyTUoxVWotYzVCWDNTRExxT2xpWlBHS29RSUM0ZG12RVBWZjdYMjlvSk9KQ3hZNkNzdEU5WS1lVS1uV0xNUVVIN182clZxWE91MEZkeXNpdE0z?oc=5","date":"2022-02-17","type":"deal","source":"Fierce Biotech","summary":"Remix Therapeutics signs Janssen licensing deal that could top $1B - Fierce Biotech","headline":"Remix Therapeutics signs Janssen licensing deal that could top $1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOamxJeF9YWHZvOHpXeEZSd0NKUmJHY1hvSE1STlRZSkhEZ1BzLUl6NlNrd1ZfOFFjaXdpOFdCcndFSFhOOTRScy1MSjhNLXVWUWttVDVDWFRxd2xUSVVIZzg3WnpKVVZxdG90S3N3LWVOOGh0cVR6UHplT3BueWppU04yVnZMREEzVlRPN0ROSmlfYlIzT1UtMkxrcFB4QTFxVlZxSWloMGo3TXVQZ09jX2FJODBvRk1aRjNvSnlOajg0UWlZMGw1ajNR?oc=5","date":"2021-05-31","type":"pipeline","source":"The Quantum Insider","summary":"Qu&Co, Janssen Pharmaceuticals to Develop and Test Quantum Computational Methods Pharma R&D - The Quantum Insider","headline":"Qu&Co, Janssen Pharmaceuticals to Develop and Test Quantum Computational Methods Pharma R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOSWpoR2t4SkE1c0ptYzRzc3V5NlJ3MGdrR2N6R0lOS0Zod0FOazhpRGlSaVl1LW5UMktlSjBHbFNCTW5xVjEyYWVMak5lV3hFMjRmR1d1NEIzNk5DSFVscTJwbmNZU1Y2MEMtaGc5M1BHQXZsYVladnk3bWFoXzZ5ajktSEtIVDF4aFI4ZVJrYlJaXzc2bFdJYTU3MVdydl9ieU1ZVW9VQ1NqN0ZHQjAwRl93ZnZnMWsxdUN0dEZvX2dmYm5zX2hrVHNjX3hxWm1reDljNDR2WWdzeVFLc2wyU0F6bDN1UzlSaWtjNU9LUWtWeUUwTjhhanhyNVMxaVMwZkkzbi1xVkVVNlpH?oc=5","date":"2020-12-02","type":"deal","source":"PR Newswire","summary":"Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration - PR Newswire","headline":"Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degener","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5kUVZmWmw5THhhcVVZbnktazByQ2NpUmZoY0Q1ZEhyT3NsRHJ5RjBrT0RELVJzRklTOTZpWUptNHVFUlhuY08yMU9BNW54bnpHc0ZQbGsyU0E?oc=5","date":"2019-12-19","type":"pipeline","source":"Nature","summary":"Dementia and Drug Discovery / Janssen Pharmaceuticals K.K. - Nature","headline":"Dementia and Drug Discovery / Janssen Pharmaceuticals K.K.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPUTBiNnBxcTJOV1dNZ2kycXNBLTIwb0R4cDI2RzFHREEtU1RsSERDTUdqd0J0N09jNnpjWjhtdUdtUjh2VGJwWWczWDdlaWFXY1hfUldFNTFBbjB0R1hqNVJ6b2xUX095T2JyYXBqME9iaW9RRERNQ1ZBcVU2YTJZZXgycndqc1Z4cWx2cTlYSWI2Z0hLdzZj?oc=5","date":"2017-02-27","type":"pipeline","source":"Johnson & Johnson","summary":"Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report - Johnson & Johnson","headline":"Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report - Johnson & Johnson","sentiment":"neutral"}],"patents":[{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"9622983","type":"Formulation","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"8663683","type":"Formulation","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"8992989","type":"Formulation","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"8889191","type":"Method of Use","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"9549940","type":"Formulation","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"8298580","type":"Formulation","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"8877248","type":"Formulation","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"9555004","type":"Formulation","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"10314790","type":"Formulation","expiryDate":"2027-11-16","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"8298576","type":"Formulation","expiryDate":"2028-04-04","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"10363224","type":"Method of Use","expiryDate":"2033-03-19","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"9555005","type":"Formulation","expiryDate":"2033-03-19","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"9101545","type":"Formulation","expiryDate":"2033-03-19","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"8889190","type":"Formulation","expiryDate":"2033-03-19","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"8652527","type":"Formulation","expiryDate":"2033-03-19","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"11433046","type":"Method of Use","expiryDate":"2040-08-21","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"12290503","type":"Formulation","expiryDate":"2040-08-21","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"11911362","type":"Formulation","expiryDate":"2040-08-21","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"11826343","type":"Formulation","expiryDate":"2040-08-21","territory":"US","genericFilings":[]},{"drugName":"Topamax","drugSlug":"topiramate","patentNumber":"11633374","type":"Formulation","expiryDate":"2040-08-21","territory":"US","genericFilings":[]}],"drugCount":211,"phaseCounts":{"marketed":61,"phase_1":42,"phase_2":25,"phase_3":77,"discontinued":6},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}